Morgan Stanley Upgrades QGEN to Buy, Sets $42 Price Target
Morgan Stanley analyst Steve Beuchaw raises QGEN's rating to Buy, targeting $42, a 8.44% upside from the current price.
Key Points
- Morgan Stanley's Steve Beuchaw upgraded QGEN to a Buy rating with a new price target of $42 on June 23, 2026.
- Morgan Stanley's $42 price target implies 8.44% upside from Qiagen N.V.'s ($QGEN) current $38.73 share price.
- Shares of QGEN traded at $36.28 on Tuesday, as the company witnessed insider selling activity in August 2025.
- Institutional investors like Wellington Management and BlackRock increased their QGEN holdings, while Deutsche Bank reduced its position.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Morgan Stanley analyst Steve Beuchaw has upgraded QGEN to a Buy rating, setting a new price target of $42. This change was announced on June 23, 2026. Shares of QGEN traded at $36.28 on Tuesday.
Morgan Stanley vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in QGEN
Several institutional investors have been active in QGEN recently. Wellington Management Group increased its holdings by 933,394 shares, bringing its total to about 14.36 million shares valued at approximately $575.1 million, a 6.9% increase. Price T Rowe Associates also added 421,381 shares, ending with about 8.43 million shares worth $337.5 million, marking a 5.3% rise. Vanguard Capital Management opened a new position with 6.11 million shares valued at $247.4 million. On the other hand, Deutsche Bank AG reduced its stake by 1,910,454 shares, now holding about 5.6 million shares worth $224.3 million, a decrease of 25.4%. BlackRock, Inc. slightly increased its position by 117,495 shares, reaching 5.25 million shares valued at $210.2 million.
Insider Buying and Selling at Qiagen N.V.
In August 2025, several insiders at QGEN sold shares. Roland Sackers sold 31,423 shares at an average price of $49.21 on August 15, and another 18,577 shares at $49.00 on August 14. Thierry Bernard also sold 25,000 shares at $48.80 on August 15. These transactions were not part of a planned sale.
Analysts Set New Price Targets
On June 23, 2026, Morgan Stanley upgraded QGEN to a Buy rating with a $42 price target. Previously, Stifel maintained a Hold rating with a $36 target on May 18, 2026. TD Cowen also maintained a Hold with a $40 target on May 7, 2026. JP Morgan maintained a Buy rating with a $45 target on April 29, 2026.
Bottom Line
Morgan Stanley's upgrade of QGEN to a Buy with a $42 target highlights growing optimism among analysts. Institutional investors are also adjusting their stakes, with some increasing their holdings while others reduce. Insider sales in 2025 suggest some executives were cashing in at higher prices. As always, these filings are backward-looking and may not reflect the current state of affairs.
Get Qiagen N.V. alerts
New 13F filings, insider trades, and analyst moves on $QGEN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.